Table 2 Comparisons among pulmonologist and non-pulmonologist physicians, according to progressionassessment of disease
Treatment | Pulmonologist | |||||||
|---|---|---|---|---|---|---|---|---|
Yes N = 91 (29.7%) | No N = 215 (70.3%) | Total | ||||||
n | % | n | % | OR (CI 95%) | n | % | p value* | |
Supplemental oxygen | 77 | 84.6 | 141 | 65.6 | 2.89 (1.53–5.45) | 218 | 71.2 | 0.001 |
Corticosteroids (CS) | 39 | 42.9 | 108 | 50.2 | 0.74 (0.45–1.22) | 147 | 48.0 | 0.238 |
Azatioprine | 5 | 5.5 | 13 | 6.0 | 0.90 (0.31–2.61) | 18 | 5.9 | 0.851 |
CS + immunosupressors (IS) | 6 | 6.6 | 26 | 12.1 | 0.51 (0.20–1.29) | 32 | 10.5 | 0.151 |
N-acetylcisteine (NAC) | 30 | 33.0 | 59 | 27.4 | 1.30 (0.77–2.21) | 89 | 29.1 | 0.331 |
Corticosteroids + NAC + IS | 14 | 15.4 | 45 | 20.9 | 0.69 (0.36–1.33) | 59 | 19.3 | 0.261 |
Corticosteroids + NAC | 17 | 18.7 | 46 | 21.4 | 0.84 (0.45–1.57) | 63 | 20.6 | 0.591 |
Colchicine | 3 | 3.3 | 11 | 5.1 | 0.63 (0.17–2.32) | 14 | 4.6 | 0.486 |
Ciclosporine | 0 | 0.0 | 2 | 0.9 | NS | 2 | 0.7 | 0.356 |
Anti-blotting | 1 | 1.1 | 15 | 7.0 | 0.15 (0.02–1.14) | 16 | 5.2 | 0.035 |
Pirfenidona | 38 | 41.8 | 14 | 6.5 | 10.29 (5.20–20.39) | 52 | 17.0 | 0.000 |
Pirferidona + NAC | 18 | 19.8 | 7 | 3.3 | 7.33 (2.94–18.25) | 25 | 8.2 | 0.000 |